publication date: Apr. 30, 2015
NCI CTEP-Approved Trials for the Month of April
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
A011203: A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer. Alliance for Clinical Trials in Oncology; Goetz, Matthew P. (507) 284-4857
EA8141: A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma. ECOG-ACRIN Cancer Research Group; Margulis, Vitaly. (214) 648-0567
NRG-GY001: A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum. NRG Oncology; Farley, John Hall. (602) 406-7730
NRG-GY002: A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer. NRG Oncology; Santin, Alessandro D. (203) 785-6301
Continue reading CCL April – NCI CTEP-Approved Trials for the Month of April
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.